Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry

Journal of Virology

Volumn 86, Issue 20, 2012, Pages 10935-10949

  Diao, Jingyu ^a   Pantua, Homer ^a   Ngu, Hai ^a   Komuves, Laszlo ^a   Diehl, Lauri ^a   Schaefer, Gabriele ^a   Kapadia, Sharookh B ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD81 ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; LAPATINIB; SMALL INTERFERING RNA;

ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; ENDOCYTOSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LIGAND BINDING; LIVER CELL; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RNA REPLICATION; VIRUS ENTRY;

ANTIGENS, CD81; CELL LINE, TUMOR; CLAUDIN-1; HEPACIVIRUS; HUMANS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNA, VIRAL; VIRUS INTERNALIZATION;

HEPATITIS C VIRUS;

EID: 84869049528     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00750-12     Document Type: Article

References (58)

1. Blanchard E, et al. 2006. Hepatitis C virus entry depends on clathrinmediated endocytosis. J. Virol. 80:6964-6972.
2. Bradley DW. 2000. Studies of non-A, non-B hepatitis and characterization of the hepatitis C virus in chimpanzees. Curr. Top. Microbiol. Immunol. 242:1-23.
3. Brazzoli M, et al. 2008. CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J. Virol. 82:8316-8329.
4. Burlone ME, Budkowska A. 2009. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J. Gen. Virol. 90:1055-1070.
5. Chan G, Nogalski MT, Yurochko AD. 2009. Activation of EGFR on monocytes is required for human cytomegalovirus entry and mediates cellular motility. Proc. Natl. Acad. Sci. U. S. A. 106:22369-22374.
6. Coffey GP, et al. 2009. Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin. J. Cell Sci. 122:3137-3144.
7. Compton T. 2004. Receptors and immune sensors: the complex entry path of human cytomegalovirus. Trends Cell Biol. 14:5-8.
8. Dreux M, et al. 2006. High density lipoprotein inhibits hepatitis C virusneutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J. Biol. Chem. 281:18285-18295.
9. Eierhoff T, Hrincius ER, Rescher U, Ludwig S, Ehrhardt C. 2010. The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells. PLoS Pathog. 6:e1001099. doi:10.1371/ journal.ppat.1001099.
10. El-Bassiouni A, et al. 2006. Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma. APMIS 114:420-427.
11. Evans MJ, et al. 2007. Claudin-1 is a hepatitis C virus coreceptor required for a late step in entry. Nature 446:801-805.
12. Farquhar MJ, et al. 2008. Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity. J. Virol. 82:8797-8811.
13. Farquhar MJ, Harris HJ, McKeating JA. 2011. Hepatitis C virus entry and the tetraspanin CD81. Biochem. Soc. Trans. 39:532-536.
14. Farquhar MJ, et al. 2012. Hepatitis C virus induces CD81 and claudin-1 endocytosis. J. Virol. 86:4305-4316.
15. Garrett CR, Eng C. 2011. Cetuximab in the treatment of patients with colorectal cancer. Expert Opin. Biol. Ther. 11:937-949.
16. Harmon B, Campbell N, Ratner L. 2010. Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a post-hemifusion step. PLoS Pathog. 6:e1000956. doi:10.1371/journal.ppat.1000956.
17. Hotzel I, et al. 2011. Efficient production of antibodies against a mammalian integral membrane protein by phage display. Protein Eng. Design Selection 24:679-689.
18. Ito Y, et al. 2001. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br. J. Cancer 84:1377-1383.
19. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM. 2007. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J. Virol. 81:8374-8383.
20. Kapadia SB, Barth H, Baumert T, McKeating JA, Chisari FV. 2007. Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J. Virol. 81:374-383.
21. Kapadia SB, Chisari FV. 2005. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc. Natl. Acad. Sci. U. S. A. 102:2561-2566.
22. Keck ZY, et al. 2007. Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J. Virol. 81:1043-1047.
23. Koike K. 2007. Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways. J. Gastroenterol. Hepatology 22(Suppl 1):S108 -S111.
24. Li S, et al. 2005. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7:301-311.
25. Lindenbach BD, et al. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626.
26. -ΔΔCT method. Methods 25: 402-408.
27. Lockhart AC, Berlin JD. 2005. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin. Oncol. 32:52-60.
28. Lupberger J, et al. 2011. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med. 17:589-595.
29. Mee CJ, et al. 2009. Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J. Virol. 83:6211-6221.
30. Mendelsohn J. 2000. Blockade of receptors for growth factors: an anticancer therapy: the fourth annual Joseph H. Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin. Cancer Res. 6:747-753.
31. Mendelsohn J. 2001. The epidermal growth factor receptor as a target for cancer therapy. Endocrine-Related Cancer 8:3-9.
32. Mendelsohn J, Baselga J. 2006. Epidermal growth factor receptor targeting in cancer. Semin. Oncol. 33:369-385.
33. Meuleman P, et al. 2008. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 48:1761-1768.
34. Miller RG, Jr. 1981. Simultaneous statistical inference, 2nd ed. Springer-Verlag, New York, NY.
35. Miyanari Y, et al. 2007. The lipid droplet is an important organelle for hepatitis C virus production. Nat. Cell Biol. 9:1089-1097.
36. Montpellier C, et al. 2011. Interacting regions of CD81 and two of its partners, EWI-2 and EWI-2wint, and their effect on hepatitis C virus infection. J. Biol. Chem. 286:13954-13965.
37. Neumann AU, et al. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103-107.
38. Odintsova E, Sugiura T, Berditchevski F. 2000. Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/ KAI-1. Curr. Biol. 10:1009-1012.
39. Odintsova E, Voortman J, Gilbert E, Berditchevski F. 2003. Tetraspanin CD82 regulates compartmentalisation and ligand-induced dimerization of EGFR. J. cell science 116:4557-4566.
40. Owsianka A, et al. 2005. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J. Virol. 79:11095-11104.
41. Pietschmann T, et al. 2006. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. U. S. A. 103:7408-7413.
42. Pileri P, et al. 1998. Binding of hepatitis C virus to CD81. Science 282: 938-941.
43. Ploss A, et al. 2009. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457:882-886.
44. Raabe EH, et al. 2011. BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. Clin. Cancer Res. 17:3590-3599.
45. Sainz B, Jr, et al. 2012. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitisCvirus entry factor. Nat. Med. 18:281-285.
46. Sandrin V, et al. 2005. Assembly of functional hepatitis C virus glycoproteins on infectious pseudoparticles occurs intracellularly and requires concomitant incorporation of E1 and E2 glycoproteins. J. Gen. Virol. 86: 3189-3199.
47. Scarselli E, et al. 2002. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21:5017-5025.
48. Schaefer G, et al. 2011. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 20:472-486.
49. Sharma NR, et al. 2011. Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion. J. Biol. Chem. 286:30361-30376.
50. Sun Y, et al. 2012. Evolutionarily conserved paired immunoglobulin-like receptor alpha (PILR_) domain mediates its interaction with diverse sialylated ligands. J. Biol. Chem. 287:15837-15850.
51. Tanaka H. 1991. Immunohistochemical studies on epidermal growth factor receptor in hepatocellular carcinoma. Nihon Shokakibyo Gakkai Zasshi 88:138-144. (In Japanese.)
52. Thoresen GH, et al. 1998. Response to transforming growth factor alpha (TGF_) and epidermal growth factor (EGF) in hepatocytes: lower EGF receptor affinity of TGF_ is associated with more sustained activation of p42/p44 mitogen-activated protein kinase and greater efficacy in stimulation of DNA synthesis. J. Cell. Physiol. 175:10-18.
53. Trotard M, et al. 2009. Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening. FASEB J. 23:3780-3789.
54. Voisset C, et al. 2008. Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry. Cell. Microbiol. 10:606-617.
55. - symporter, induces apoptosis in human and rat hepatocellular cancer cell lines in vitro and inhibits the growth of hepatocellular carcinoma xenografts in nude mice. Hepatology 30:894-902.
56. Yarden Y, Sliwkowski MX. 2001. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2:127-137.
57. Zeisel MB, et al. 2007. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 46:1722-1731.
58. Zhong J, et al. 2005. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 102:9294-9299.